Skip to main content

BEYFORTUS nirsevimab 100mg/1mL injection solution in pre-filled syringe (Germany)​

Section 19A approved medicine
BEYFORTUS nirsevimab 100mg/1mL injection solution in pre-filled syringe (Germany)​
Section 19A approval holder
Sanofi-Aventis Australia Pty Ltd ABN 31 008 558 807
Phone
1800 818 806
Approved until
Status
Current
Medicines in short supply/unavailable
BEYFORTUS nirsevimab 100mg in 1mL solution for injection prefilled syringe - ARTG 397899
Indication(s)

BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

BEYFORTUS should be used in accordance with official recommendations.

Images
Picture of BEYFORTUS nirsevimab 100mg/1mL injection solution in pre-filled syringe - box

Help us improve the Therapeutic Goods Administration site